Lexon acquires lung cancer assay via Cancer Diagnostic Inc purchase:
This article was originally published in Clinica
Executive Summary
Lexon, a diagnostic company in Tulsa, Oklahoma, has obtained exclusive rights to its Telomerase Assay, a patent-pending blood test for lung cancer, through the $200,000 acquisition of Cancer Diagnostic Inc (CDI), a division of the Plant City, Florida-based company, Utek. The assay came from research conducted at the University of Maryland, Baltimore Medical Center, by Dr Edward Highsmith, who will continue to oversee research and commercialisation. Lexon also owns exclusive rights to the Ebaf Assay, a blood test for colon cancer screening. The acquisition - in cash and notes - was made in lieu of the previously announced merger of CDI into Lexon and eliminates the requirement under the merger agreement to issue 500,000 shares to CDI.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.